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Progressive multifocal leukoencephalopathy (PML) is a 
rapidly progressive demyelinating disease of the central 
nervous system caused by John Cunningham polyomavirus 
(JCV), a globally seroprevelant virus that commonly causes 
a silent or benign infection. However, in immunocompro-
mised patients JCV can be reactivated. In this situation, most 
organs remain unaffected, but multiplication within oligo-
dendrocytes causes lytic brain lesions resulting in progres-
sive motor dysfunction, cognitive impairment, and visual 
deficits. Although some strategies are available for treat-
ment, particularly if recognised early, PML has an overall 
mortality of 30–50% and can result in substantial morbidity.
Progressive multifocal leukoencephalopathy is thank-
fully rare and most commonly associated with lymphopro-
liferative disease or advanced human immunodeficiency 
virus (HIV) infection. However, PML is now well known 
to be associated with the use of disease modifying therapies 
(DMTs) in multiple sclerosis (MS) such as natalizumab that 
alter cell-mediated immunity. Given the serious implications 
of a diagnosis of PML, patients now undergo a process of 
risk stratification at commencement of treatment and then 
selective serological testing over the course of treatment, 
interval magnetic resonance imaging (MRI) and regular clin-
ical surveillance to identify any early pathological changes. 
Once a diagnosis is established, current treatment strategies 
include withdrawal of immunosuppressive therapies, plasma 
exchange (PLEX), mirtazapine, mefloquine as well as strate-
gies to up regulate patient immunity.
This month’s journal club reviews three new potential 
treatment options in the management of PML. The first 
paper reviews the use of pembrolizumab, the second allo-
geneic BK virus-specific T cells and the third filgrastim.
Pembrolizumab treatment for progressive 
multifocal leukoencephalopathy
Pembrolizumab is a monoclonal antibody used as an immu-
notherapy in conditions such as melanoma or non-small 
cell lung cancer. It is designed to block the expression of 
programme cell death protein 1 (PD-1) expressed on the 
surface of T cells. This protein acts as a negative regula-
tor of immune cells and prolonged expression, such as that 
observed in chronic infections can lead to suppression of T 
cell activity and repertoire. Significantly, PD-1 expression 
was found to be up-regulated on CD4+ and CD8+ cells in 
patients with PML and is specifically enriched on JCV-spe-
cific CD8+ cells. It was therefore hypothesised that blockade 
of PD-1 in PML would allow reinvigoration of the T cell 
response and suppression of PML.
Eight adults with PML were identified and had a range 
of underlying conditions including chronic lymphoid leu-
kaemia, advanced HIV infection, Hodgkin’s and non-Hodg-
kin’s lymphoma and idiopathic lymphopenia. The major-
ity had been treated with chemotherapy or DMT agents 
in the past. All continued to have detectable viral loads of 
JCV in the cerebral spinal fluid (CSF) ranging from 63 to 
28,350 copies per millilitre at entry into the study. Pem-
brolizumab was given intravenously at a dose of 2 mg per 
kg every 4–6 weeks, for a maximum of three doses. Clini-
cal evaluations included neurologic examination, use of a 
modified Rankin scale to assess disability, MRI, CSF and 
blood testing.
Five of the eight patients exhibited clinical improve-
ment or stabilisation of neurological symptoms, reduction 
in CSF JCV viral load and corresponding stabilisation or 
reduction in lesion burden on MRI brain. One exhibited no 
clinical improvement, but in retrospect was noted to have 
had some clinical, radiologic, and virologic stabilisation of 
PML before treatment. The remaining two patients worsened 
clinically and subsequently died. No patients had complete 
resolution of PML brain lesions. Apart from two patients 
who developed a rash, the drug was well tolerated.
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Comment: This novel study repurposed an existing can-
cer immunotherapy following important pathophysiological 
observations by the authors. This study is clearly limited by 
its sample size and heterogeneous patient cohort but offers 
some promise as well as a useful model for evaluation of 
novel treatments in PML. Although difficult, given the rar-
ity of PML, future studies exploring more specified patient 
groups, such as Natalizumab induced PML in MS as well 
as development of a standardised way of determining and 
monitoring disease state and severity would be of value.
Cortese I et al (2019) N Engl J Med 380:1597–1605.
Allogeneic BK virus‑specific T 
cells for progressive multifocal 
leukoencephalopathy
The BK virus belongs to the same polyomaviridae family 
as JCV and is genetically similar with a number of shared 
immunogenic proteins. Clinically BK virus causes nephri-
tis and cystitis in patients who have undergone solid organ 
or stem-cell transplantation. BK virus has previously been 
treated with viral-specific T cells and it was hypothesised 
that given the shared epitopes of BK and JCV that this treat-
ment could also be successful in PML.
This study utilised BK virus-specific T cells generated 
from 27 healthy donors. The most closely HLA-matched 
T cell line for each patient was chosen and via intravenous 
infusion, a dose of 2 × 105 T cells per kg every 4 weeks was 
given until JCV was cleared from the CSF. Three patients 
with PML were identified for the study, the first had a diag-
nosis of acute myeloid leukaemia treated with cord–blood 
transplant the second patient had a myeloproliferative neo-
plasm treated with ruxolitinib and the third patient had 
chronic HIV infection previously treated with highly active 
antiretroviral therapy.
After treatment, two patients had an improvement in 
clinical status, imaging features of PML and in both JCV 
was successfully cleared from the CSF. Both patients also 
had radiological evidence of immune reconstitution inflam-
matory syndrome (IRIS), but no relevant clinical manifes-
tations. The third patient had a reduction in JC viral load 
and symptom stabilisation but died 8 months after the last 
infusion; cause of death was not reported.
Comment: This proof of concept study confirmed that 
JCV can be cleared from CSF and the clinical features of 
PML improved using a third party partial HLA matched T 
cell specific BK virus treatment. These positive responses 
occurred despite evidence of persistent T cell immunode-
ficiency, even with radiological evidence of IRIS suggest-
ing inflammatory upregulation at the site of PML infec-
tion caused by the infused T cells. Supportive evidence 
was also offered by measurement of the infused T cells in 
the CSF for more than 250 days after treatment. No graft 
versus host disease was observed although this may have 
been as the result of the immunocompromised state of the 
patients. Although patient specific T cell treatments may 
improve outcomes and reduce the risk of inflammatory 
sequelae the use of ‘off-the-shelf’ medication as in this 
study, provides a novel rapid method to treat this debilitat-
ing condition.
Muftuoglu M et al (2018) N Engl J Med 379:1443–1451.
Treatment of natalizumab‐associated PML 
with filgrastim
As of December 2018, there have been 801 confirmed 
cases of natalizumab induced PML in MS, with mortality 
rates of 8–29%. Filgrastim (also known as granulocyte-
colony stimulating factor) is used widely to upregulate the 
immune system after chemotherapy. It promotes produc-
tion of granulocytes, lymphocytes and antigen present-
ing cells, while also increasing adhesive properties of T 
cells independent of integrin α4β1; the adhesin blocked 
by natalizumab.
This study was a retrospective analysis of 17 natali-
zumab induced PML cases in MS from 2010 to 2017 in a 
single centre. PML occurred on average after 49 infusions 
of natalizumab. Fifteen patients had clinical features con-
sistent with PML and two were identified through routine 
surveillance MRI. Following diagnosis natalizumab was 
stopped in all patients, 8 underwent PLEX, 14 received 
mefloquine and 15 received Mirtazapine. All patients were 
then treated with daily filgrastim 5 µg/kg subcutaneously 
until baseline absolute lymphocyte counts were approxi-
mately doubled, which occurred at a mean of 9.94 days. 
Once PML-IRIS was confirmed (at a mean of 57.4 days) 
in 15 patients, they were also treated with intravenous 
Methylprednisolone followed by a tapering dose of oral 
corticosteroids. Nine of these patients were also treated 
with maraviroc to dampen the IRIS response. Using a 
Karnofsky functionality scoring system, seven patients 
recovered to or near the PML diagnosis baseline, three 
improved, but not to baseline functionality and seven had 
poor outcomes requiring full care. There was no evidence 
for the worsening of MS with any of the above procedures, 
with three patients having an MS relapse within a year of 
PML diagnosis.
Comment: This retrospective study explored the open 
label use of filgrastim in natalizumab induced PML. 
Although 100% of patients survived for at least 2 years, 
the use of a variety of parallel treatment regimes limits 
interpretation of outcomes and the significance of any 
additional beneficial effect for filgrastim in these cir-
cumstances. Nevertheless, careful surveillance for PML, 
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immune activation by filgrastim and subsequent PML-IRIS 
management in combination appeared beneficial. Further 
work to define the most appropriate management strat-
egy would be of value. In addition, the use of a relatively 
homogenous MS cohort was useful in order to provide 
clinicians with informed strategies to manage natalizumab 
induced PML and council patients as to the risk of their 
MS deteriorating.
Stefoski D et  al (2019) Ann Clin Transl Neurol 6: 
923–931.
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